Arovella Therapeutics Share Price and Company Fundamentals

0.002 (5.128%)
52 week
0.033 - 0.075

Last traded: Today at 1:14 AM

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. The company's product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; Sumatriptan, an oral spray formulation for the treatment of migraine headache; and Anagrelide to treat cancer. It has a license and supply agreement with Cann Pharmaceutical Australia Limited to develop an oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug-resistant epilepsy, melanoma and Sanofi; and collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield



Market cap


Enterprise value


Company profile

Primary activitiesDevelopment and commercialisation of pharmaceutical products through new methods of delivery.
Industry / SectorBiotechnology / Healthcare
Mailing address55 Howe Street Level 1 Unit 12 Osborne Park WA 6017 Australia
Phone / Fax61 8 6142 5555 /


Arovella Therapeutics does not pay dividends.

Company Executives

As of Jan 2022, following are the company executives and directors listed on Arovella Therapeutics.

NameTitleAgeTotal Pay
Dr. Michael BakerCEO, MD & Director376.12k
Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBACompany Sec. & CFO60
Mr. Stephen John CarterConsultant
Dr. Richard FranklinProject Director & Member of Scientific Advisory Board
Tony MacintyreGM & CTO

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Arovella Therapeutics is and its enterprise value is .

Companies similar to Arovella Therapeutics (ALA)

Arovella Therapeutics (ASX:ALA) Frequently Asked Questions

1. What is Arovella Therapeutics's Stock Symbol?

Arovella Therapeutics trades on ASX under the ticker symbol "ALA".

2. What is Arovella Therapeutics's stock price today?

One share of ALA stock can currently be purchased for approximately $0.041.

3. How can I contact Arovella Therapeutics?

Arovella Therapeutics's mailing address is 55 Howe Street Level 1 Unit 12 Osborne Park WA 6017 Australia. The company can be reached via phone at 61 8 6142 5555.

4. What is Arovella Therapeutics's official website?

The official website of Arovella Therapeutics is

5. Which share registry manages Arovella Therapeutics's stock?

Arovella Therapeutics's stock is managed by ADVANCED SHARE REGISTRY SERVICES.